Mapping Aptamer Prototypes to the Unmet Gaps of Glioblastoma Care: From Circulating Cells to the Resection Cavity
- 1Laboratory for Digital Controlled Drugs and Theranostics, Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Krasnoyarsk 660036, Russia
- 2Laboratory for Biomolecular and Medical Technologies, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
- 3Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
Abstract
Background: Glioblastoma remains poorly controlled despite maximal safe resection, radiotherapy, and temozolomide. Six problems remain unresolved along this pathway: epithelial-marker-based capture can miss glial cells; infiltration extends beyond visible margins; residual disease survives resection; the blood–brain barrier restricts delivery; receptor switching and stem-like states enable escape; and immune control remains inadequate. This review considers aptamer approaches to these limitations while distinguishing experimental candidates from clinical practice. Methods: This narrative synthesis incorporates PubMed records, supplementary Google Scholar searches, primary experimental and clinical reports, and registry verification. Evidence is distinguished by tumor type, model, route, and endpoint; no meta-analysis was performed. Results: An EpCAM-independent DNA aptamer supports circulating glioma-cell isolation in a small patient series. A near-infrared conjugate labels ex vivo human tissue and animal tumors, but its reported study did not include intraoperative use in patients. Antagonists, photodynamic constructs, and magnetic nanodiscs provide preclinical approaches to tumor-cell control; nanodisc evidence includes separate ascites and glioblastoma studies. Delivery platforms range from receptor-targeted nanoparticles and STAT3 siRNA chimeras to aptamer–drug conjugates selected in orthotopic patient-derived xenografts. Combined receptor blockade and EphA2 targeting address escape experimentally. GLORIA has published phase I/II dose-escalation and bevacizumab-expansion cohorts for the CXCL12-binding L-RNA olaptesed pegol, while a bispecific 4-1BB–osteopontin aptamer provides glioma-specific preclinical immune-directed evidence. Conclusions: Selected studies are relevant to each limitation, but heterogeneous evidence and conceptual selection preclude claims of comprehensive coverage or clinical resolution. Local cavity delivery remains a development hypothesis requiring independent safety and efficacy assessment. Aptamers should complement—not replace—established care.
Related
- Reconciling Extent of Resection and Residual Tumor Volume in Glioblastoma: Sources of Discordance and a Proposed Reporting Framework
- Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma
- Liquid biopsy using circulating miRNAs for the identification of recurrence-associated biomarkers in glioblastoma CNS WHO grade 4
- Hiporfin (HpD) for fluorescence-guided resection of recurrent glioblastoma: diagnostic accuracy and feasibility of an integrated photodynamic strategy
- Privacy-preserving clustered federated learning via differential privacy and homomorphically encrypted prototypes
BibTeX
@article{zamay2026mapping,
title = {{Mapping Aptamer Prototypes to the Unmet Gaps of Glioblastoma Care: From Circulating Cells to the Resection Cavity}},
author = {Galina S. Zamay and Natalia A. Luzan and Anastasia A. Koshmanova and Tatiana N. Zamay and Olga S. Kolovskaya and Maxim V. Berezovski and Anna S. Kichkailo},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213474},
url = {https://www.mdpi.com/2072-6694/18/21/3474},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mapping Aptamer Prototypes to the Unmet Gaps of Glioblastoma Care: From Circulating Cells to the Resection Cavity
AU - Galina S. Zamay
AU - Natalia A. Luzan
AU - Anastasia A. Koshmanova
AU - Tatiana N. Zamay
AU - Olga S. Kolovskaya
AU - Maxim V. Berezovski
AU - Anna S. Kichkailo
PY - 2026
DA - 2026/10/28
JO - Cancers
DO - 10.3390/cancers18213474
UR - https://www.mdpi.com/2072-6694/18/21/3474
AB - Background: Glioblastoma remains poorly controlled despite maximal safe resection, radiotherapy, and temozolomide. Six problems remain unresolved along this pathway: epithelial-marker-based capture can miss glial cells; infiltration extends beyond visible margins; residual disease survives resection; the blood–brain barrier restricts delivery; receptor switching and stem-like states enable escape; and immune control remains inadequate. This review considers aptamer approaches to these limitations while distinguishing experimental candidates from clinical practice. Methods: This narrative synthesis incorporates PubMed records, supplementary Google Scholar searches, primary experimental and clinical reports, and registry verification. Evidence is distinguished by tumor type, model, route, and endpoint; no meta-analysis was performed. Results: An EpCAM-independent DNA aptamer supports circulating glioma-cell isolation in a small patient series. A near-infrared conjugate labels ex vivo human tissue and animal tumors, but its reported study did not include intraoperative use in patients. Antagonists, photodynamic constructs, and magnetic nanodiscs provide preclinical approaches to tumor-cell control; nanodisc evidence includes separate ascites and glioblastoma studies. Delivery platforms range from receptor-targeted nanoparticles and STAT3 siRNA chimeras to aptamer–drug conjugates selected in orthotopic patient-derived xenografts. Combined receptor blockade and EphA2 targeting address escape experimentally. GLORIA has published phase I/II dose-escalation and bevacizumab-expansion cohorts for the CXCL12-binding L-RNA olaptesed pegol, while a bispecific 4-1BB–osteopontin aptamer provides glioma-specific preclinical immune-directed evidence. Conclusions: Selected studies are relevant to each limitation, but heterogeneous evidence and conceptual selection preclude claims of comprehensive coverage or clinical resolution. Local cavity delivery remains a development hypothesis requiring independent safety and efficacy assessment. Aptamers should complement—not replace—established care.
SN - 2072-6694
ER -